Search results for "Original article"

showing 10 items of 1187 documents

Effectiveness of training in guideline-oriented biopsychosocial management of low-back pain in occupational health services – a cluster randomized co…

2021

Objective This study aimed to investigate the effectiveness of brief training in the guideline-oriented biopsychosocial management of low-back pain (LBP) in occupational health services using a cluster-randomized design. A small sample of physiotherapists and physicians from the intervention units (N=12) were given three- to seven-day training focusing on the biopsychosocial management of LBP, while professionals in the control units (N=15) received no such training. Methods Eligible patients with LBP, with or without radicular pain, aged 18-65, were invited to participate. A web-based questionnaire was sent to all recruited patients at baseline, three months and one year. The primary outco…

Biopsychosocial modelmedicine.medical_specialtytyöterveyshuoltocluster randomized controlled trialOccupational Health Servicespsykososiaaliset tekijätrisk stratificationoccupational health servicebiopsychosocialOccupational safety and healthlaw.inventionlow-back painRandomized controlled trialselkäsairaudetimplementation researchlawSurveys and QuestionnairesmedicineHumanspainSjukgymnastikPhysiotherapyPain Measurementtrainingbusiness.industryimplementation research; risk stratification; STarT Back Tool; Orebro Musculoskeletal Pain Screening Questionnairestart back toolPublic Health Environmental and Occupational HealthGuidelinemedicine.diseaseLow back pain3142 Public health care science environmental and occupational healthConfidence intervalExercise TherapyOswestry Disability IndexRadicular painoccupational healthPhysical therapykrooninen kipuörebro musculoskeletal pain screening questionnaireOriginal ArticlekuntoutusPublic aspects of medicineRA1-1270medicine.symptombusinessLow Back PainSTarT Back ToolÖrebro Musculoskeletal Pain Screening QuestionnaireScandinavian Journal of Work, Environment & Health
researchProduct

Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study

2020

Abstract Purpose To evaluate factors influencing the insulin and levothyroxine requirement in patients with autoimmune polyglandular syndrome type 3 (APS-3) vs. patients with type 1 diabetes mellitus (T1DM) and autoimmune hypothyroidism (AH) alone, respectively. Methods Fifty patients with APS-3, 60 patients with T1DM and 40 patients with AH were included. Anthropometric, clinical and biochemical parameters were evaluated in all patients. Insulin requirement was calculated in patients with APS-3 and T1DM, while levothyroxine requirement was calculated in APS-3 and AH. Results Patients with APS-3 showed higher age (p = 0.001), age of onset of diabetes (p = 0.006) and TSH (p = 0.004) and lowe…

Blood GlucoseMale0301 basic medicineendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipose tissueGastroenterologySettore MED/13 - Endocrinologia0302 clinical medicineEndocrinologyAutoimmune hypothyroidism Cardiovascular risk Irisin Type 1 diabetes mellitus Visceral adiposity indexInsulinPolyendocrinopathies AutoimmuneThyroid diseaseMiddle AgedPrognosisFemaleOriginal Articlemedicine.drugAdultIrisinmedicine.medical_specialtyWaistAdolescentLevothyroxineType 1 diabetes mellitus030209 endocrinology & metabolismHashimoto DiseaseYoung Adult03 medical and health sciencesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAgedType 1 diabetesAutoimmune hypothyroidismbusiness.industryInsulinThyroiditis AutoimmuneCardiovascular riskmedicine.diseaseVisceral adiposity indexThyroxineDiabetes Mellitus Type 1030104 developmental biologyAge of onsetbusinessBiomarkersFollow-Up StudiesJournal of Endocrinological Investigation
researchProduct

Glucose regulation and physical performance among older people: the Helsinki Birth Cohort Study

2018

Aims To assess whether disturbances in glucose regulation are associated with impairment in physical performance during a 10-year follow-up. Methods 475 Men and 603 women from the Helsinki Birth Cohort Study were studied. Glucose regulation was evaluated with a 2-h 75-g oral glucose tolerance test (OGTT) in 2001-2004. Subjects were categorised as having either impaired fasting glucose (IFG), impaired glucose tolerance (IGT), newly diagnosed diabetes or previously known diabetes. Physical performance was assessed approximately 10 years later using the validated senior fitness test (SFT). The relationship between glucose regulation and the overall SFT score was estimated using multiple linear…

Blood GlucoseMaleAgingFITNESSEpidemiologyEndocrinology Diabetes and MetabolismPhysical fitnessCohort StudiesImpaired glucose toleranceMUSCLE STRENGTHDiabetes mellitus0302 clinical medicineEndocrinologyglukoosi-intoleranssiEpidemiology030212 general & internal medicineepidemiologiaFinlandAged 80 and overeducation.field_of_studyGlucose tolerance testdiabetesmedicine.diagnostic_testINDEPENDENCEGeneral Medicinefyysinen kuntodiabetes mellitusOriginal ArticleFemaleHEALTHmedicine.medical_specialtyBODY-COMPOSITIONPopulation030209 endocrinology & metabolismglucose tolerance testIMPAIRMENTSPrediabetic State03 medical and health sciencesUS ADULTSInternal medicineDiabetes mellitusGlucose IntoleranceInternal MedicinemedicineHumanseducationAgedbusiness.industryDISABILITYPhysical fitnessGlucose Tolerance Testmedicine.diseaseImpaired fasting glucoseHIGH-RISKAgeingikääntyminenverensokeri3121 General medicine internal medicine and other clinical medicineBlood sugar regulation3111 BiomedicinebusinessMEXICAN-AMERICANSFollow-Up StudiesActa Diabetologica
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Hypothalamic reactive oxygen species are required for insulin-induced food intake inhibition: an NADPH oxidase-dependent mechanism

2009

1939-327X (Electronic) Journal Article Research Support, Non-U.S. Gov't; OBJECTIVE: Insulin plays an important role in the hypothalamic control of energy balance, especially by reducing food intake. Emerging data point to a pivotal role of reactive oxygen species (ROS) in energy homeostasis regulation, but their involvement in the anorexigenic effect of insulin is unknown. Furthermore, ROS signal derived from NADPH oxidase activation is required for physiological insulin effects in peripheral cells. In this study, we investigated the involvement of hypothalamic ROS and NADPH oxidase in the feeding behavior regulation by insulin. RESEARCH DESIGN AND METHODS: We first measured hypothalamic RO…

Blood GlucoseMaleReactive Oxygen Species/*metabolismHypothalamusHomeostasis/drug effects/physiologyInbred C57BLCerebral VentriclesCerebral Ventricles/drug effects/*physiologyMiceHomeostasisInsulinAnimalsBlood Glucose/metabolismHypothalamus/*physiologyInsulin/administration & dosage/blood/*pharmacologyNADPH OxidasesEnergy Intake/drug effects/*physiologyNADPH Oxidase/*metabolismGlutathioneGlutathione/metabolismMice Inbred C57BLOriginal ArticleEnergy IntakeReactive Oxygen SpeciesEnergy MetabolismSignal Transduction
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis.

2015

Aims/Introduction According to some authors, in type 2 diabetes there is a reduced postprandial action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, little is known about the role of fasting incretins in glucose homeostasis. Our aim was to evaluate, through a two-step cluster analysis, the possibility of phenotyping patients with type 2 diabetes at onset on the basis of fasting GLP-1, GIP and ghrelin. Materials and Methods A total of 96 patients with type 2 diabetes within 6 months of onset (mean age 62.40 ± 6.36 years) were cross-sectionally studied. Clinical, anthropometric and metabolic parameters were evaluated. At fasting the follow…

Blood GlucoseMalemedicine.medical_treatmentEndocrinology Diabetes and MetabolismSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineGlucagon-Like Peptide 1Glucose homeostasisCluster AnalysisHomeostasis030212 general & internal medicineGeneral MedicineArticlesMiddle AgedGlucagon-like peptide-1GhrelinGlucagon‐like peptide‐1PhenotypeClinical Science and CareFemaleOriginal Articlehormones hormone substitutes and hormone antagonistsGlucagon-like peptide-1medicine.medical_specialtyGlucose-dependent insulinotropic polypeptideIncretin030209 endocrinology & metabolismGastric Inhibitory PolypeptideGhrelin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Endocrinology Diabetes and Metabolism; Internal MedicineIncretins03 medical and health sciencesInsulin resistanceGlucose‐dependent insulinotropic polypeptideInternal medicineDiabetes mellitusmedicineInternal MedicineHumansAgedAdiponectinbusiness.industryInsulinmedicine.diseaseEndocrinologyGlucosechemistryDiabetes Mellitus Type 2Glycated hemoglobinInsulin ResistancebusinessJournal of diabetes investigation
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Dual role of the p38 MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists.

2013

p38 Mitogen-activated protein (MAP) kinase is involved in the apoptosis of nucleated cells. Although platelets are anucleated cells, apoptotic proteins have been shown to regulate platelet lifespan. However, the involvement of p38 MAP kinase in platelet apoptosis is not yet clearly defined. Therefore, we investigated the role of p38 MAP kinase in apoptosis induced by a mimetic of BH3-only proteins, ABT-737, and in apoptosis-like events induced by such strong platelet agonists as thrombin in combination with convulxin (Thr/Cvx), both of which result in p38 MAP kinase phosphorylation and activation. A p38 inhibitor (SB202190) inhibited the apoptotic events induced by ABT-737 but did not influ…

Blood PlateletsCancer ResearchcPLA2p38 mitogen-activated protein kinasesImmunologyBlotting Westernp38 Mitogen-Activated Protein KinasesPiperazinesNitrophenolsCellular and Molecular NeurosciencePhospholipase A2Crotalid VenomsHumansLectins C-Typeddc:610Cells CulturedMembrane Potential MitochondrialplateletSulfonamidesbiologyKinaseGroup IV Phospholipases A2Biphenyl CompoundsapoptosisConvulxinCell BiologyFlow Cytometryp38 MAP kinaseCell biologyApoptosisMitogen-activated protein kinasebiology.proteinPhosphorylationOriginal ArticleSignal transductionReactive Oxygen SpeciesSignal TransductionCell deathdisease
researchProduct

Meprin β: A novel regulator of blood–brain barrier integrity

2020

The metalloprotease meprin β (Mep1b) is capable of cleaving cell-adhesion molecules in different tissues (e.g. skin, kidney and intestine) and is dysregulated in several diseases associated with barrier breakdown (Alzheimer´s disease, kidney disruption, inflammatory bowel disease). In this study, we demonstrate that Mep1b is a novel regulator of tight junction (TJ) composition and blood–brain barrier (BBB) integrity in brain endothelium. In Mep1b-transfected mouse brain endothelial cells (bEnd.3), we observed a reduction of the TJ protein claudin-5, decreased transendothelial electrical resistance (TEER) and an elevated permeability to paracellular diffusion marker [14C]-inulin. Analysis o…

Blood–brain barrierOccludinMice03 medical and health sciences0302 clinical medicineCerebrospinal fluidIn vivomedicineAnimalsHumans030304 developmental biology0303 health sciencesMetalloproteinaseKidneyTight Junction ProteinsTight junctionChemistryBrainEndothelial CellsMetalloendopeptidasesOriginal ArticlesCell biologymedicine.anatomical_structureNeurologyBlood-Brain BarrierParacellular transportNeurology (clinical)Cardiology and Cardiovascular Medicine030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct